NCT00435396View on ClinicalTrials.gov

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

February 22, 2007

Primary Completion Date

August 27, 2008

Study Completion Date

August 27, 2008

Conditions

Infections, Cytomegalovirus

Interventions

BIOLOGICAL

GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A

Intramuscular injection, 3 doses

Trial Locations (2)

2610

GSK Investigational Site, Wilrijk

7100

GSK Investigational Site, La Louvière

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY